Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
Brief Summary: After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI). Subjects will then be randomized to receive any one of the 3 treatments (umeclidinium bromide \[UMEC\] \[62.5 mcg\] administered once daily via a DPI; OR UMEC \[125 mcg\] administered once daily via a DPI; OR matching placebo administered once daily via a DPI), while continuing treatment with open label FF/VI 100/25 mcg during a 12-week treatment period. There will be a total of eight scheduled clinic visits at Pre-Screening (Visit0), Screening (Visit 1), blinded treatment Day 1(Visit2), 2(Visit3), 28 (Visit4), 56 (Visit5), 84 (Visit6) and 85 (Visit7). A follow-up phone contact will be conducted approximately 7 days after the last clinic visit. The total duration of subject participation in the study from Screening to Follow-up will be approximately 17 weeks.


Options:
A: Arm Label: Umeclidinium 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium | Arm Label: Glycopyrronium 44 mcg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): Glycopyrronium 44 mcg
B: Arm Label: GSK573719, GW642444, GSK573719+GW642444, placebo; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719, GW642444, GSK573719+GW642444, placebo
C: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 4; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Intervention Type: DRUG; Name: FF 400 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: UMEC 500 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: UMEC 250 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: VI 100 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4
D: Arm Label: FF/VI 100/25 mcg + UMEC (62.5mcg); Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: UMEC | Arm Label: FF/VI 100/25 mcg + UMEC (125mcg); Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: UMEC | Arm Label: FF/VI 100/25 mcg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: Placebo | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo, FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: VI; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo, FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: UMEC; Assigned to Arm(s): FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo

Answer: D